Schedule 13G ownership disclosure

Tenax Therapeutics, Inc.

Common Stock, $0.0001 par value per share · CUSIP: 88032L605

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOTECHNOLOGY VALUE FUND L P

    Shares: 596,433.00 · Class: 7.8%

  • BVF I GP LLC

    Shares: 596,433.00 · Class: 7.8%

  • BIOTECHNOLOGY VALUE FUND II LP

    Shares: 165,382.00 · Class: 2.3%

  • BVF II GP LLC

    Shares: 165,382.00 · Class: 2.3%

  • Biotechnology Value Trading Fund OS LP

    Shares: 0.00 · Class: 0%

  • BVF Partners OS Ltd.

    Shares: 0.00 · Class: 0%

  • BVF GP HOLDINGS LLC

    Shares: 761,815.00 · Class: 9.9%

  • BVF PARTNERS L P/IL

    Shares: 768,200.00 · Class: 9.99%

  • BVF INC/IL

    Shares: 768,200.00 · Class: 9.99%

  • LAMPERT MARK N

    Shares: 768,200.00 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-26-000474
Form type
SCHEDULE 13G/A
Filer
BIOTECHNOLOGY VALUE FUND L P
CIK
CIK 918923
Filed
Feb 17, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub